Hepatitis B Virus Research in South Africa
暂无分享,去创建一个
A. Ely | K. Bloom | M. B. Maepa | P. Arbuthnot | A. Kramvis | T. Maponga | K. Naidoo | Omphile E. Simani | Tongai Gibson Maponga
[1] C. de Martel,et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review , 2022, The lancet. Gastroenterology & hepatology.
[2] R. Parboosing,et al. Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa , 2022, Viruses.
[3] Moganavelli Singh,et al. Poly-L-Lysine–Lactobionic Acid-Capped Selenium Nanoparticles for Liver-Targeted Gene Delivery , 2022, International journal of molecular sciences.
[4] M. Sonderup,et al. Global Disparities in Hepatitis B Elimination—A Focus on Africa , 2022, Viruses.
[5] V. Bockstal,et al. Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen , 2021, NPJ vaccines.
[6] M. B. Maepa,et al. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics , 2021, Virology journal.
[7] A. Ely,et al. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors , 2021, Viruses.
[8] P. van Damme,et al. Hepatitis B Vaccines , 2021, The Journal of infectious diseases.
[9] E. Amponsah-Dacosta. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? , 2021, World journal of gastroenterology.
[10] J. Tregoning,et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.
[11] D. Curiel,et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic , 2021, NPJ vaccines.
[12] T. Cathomen,et al. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains , 2021, Viruses.
[13] K. Bloom,et al. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach , 2021, World journal of gastroenterology.
[14] A. Kramvis,et al. In vitro expression of precore proteins of hepatitis B virus subgenotype A1 is affected by HBcAg, and can affect HBsAg secretion , 2021, Scientific reports.
[15] Moganavelli Singh,et al. Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro , 2021, Pharmaceutics.
[16] R. Bruno,et al. Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? , 2021, Future oncology.
[17] S. Migueles,et al. A replication competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. , 2021, The Journal of clinical investigation.
[18] Moganavelli Singh,et al. Lactobionic acid-chitosan functionalised gold-coated poly(lactide-co-glycolide) nanoparticles for hepatocyte targeted gene delivery , 2021 .
[19] M. Fox,et al. Health provider perspectives on the implementation of the same-day-ART initiation policy in the Gauteng province of South Africa , 2021, Health Research Policy and Systems.
[20] J. Singh,et al. High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa , 2020, BMC Infectious Diseases.
[21] E. Kostaki,et al. Global and regional dispersal patterns of hepatitis B virus genotype E from and in Africa: A full-genome molecular analysis , 2020, PloS one.
[22] J. Blackard,et al. Molecular and serological characterization of occult hepatitis B among blood donors in Maputo, Mozambique , 2020, Memorias do Instituto Oswaldo Cruz.
[23] A. Neugut,et al. Hepatitis B virus-associated hepatocellular carcinoma in South Africa in the era of HIV , 2020, BMC Gastroenterology.
[24] W. Preiser,et al. Prevalence of chronic HBV infection in pregnant woman attending antenatal care in a tertiary hospital in Mwanza, Tanzania: a cross-sectional study , 2020, BMC Infectious Diseases.
[25] A. Kramvis,et al. Molecular characterization of hepatitis B virus isolated from Black South African cancer patients, with and without hepatocellular carcinoma , 2020, Archives of Virology.
[26] J. Blackard,et al. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans , 2020, Viruses.
[27] J. Seeley,et al. Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis , 2020, PLoS medicine.
[28] D. Bonsall,et al. Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults , 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[29] A. Kramvis. Challenges for hepatitis B virus cure in resource-limited settings in sub-Saharan Africa. , 2020, Current opinion in HIV and AIDS.
[30] J. Kao,et al. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy , 2020, Clinical Microbiology Reviews.
[31] C. Penny,et al. Monitoring of intracellular localization of Hepatitis B virus P22 protein using Laser Scanning Confocal Microscopy and Airyscan , 2020, Microscopy research and technique.
[32] C. Fraser,et al. Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa , 2020, Wellcome open research.
[33] P. Easterbrook,et al. Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis , 2019, Journal of viral hepatitis.
[34] S. Taylor-Robinson,et al. Hepatitis B in sub‐Saharan Africa—How many patients need therapy? , 2019, Journal of viral hepatitis.
[35] C. Winkler,et al. The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis , 2019, Cells.
[36] P. Revill,et al. Analysis of the in vitro replication phenotype of African hepatitis B virus (HBV) genotypes and subgenotypes present in Australia identifies marked differences in DNA and protein expression. , 2019, Virology.
[37] W. Preiser,et al. Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort , 2019, The Journal of infection.
[38] T. Cathomen,et al. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA , 2019, BMC Infectious Diseases.
[39] E. Bernasconi,et al. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. , 2019, Journal of hepatology.
[40] E. Barnes,et al. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa , 2019, BMC Public Health.
[41] A. Kramvis,et al. Response of hepatitis B virus to antiretroviral treatment containing lamivudine in HBsAg‐positive and HBsAg‐negative HIV‐positive South African adults , 2018, Journal of medical virology.
[42] Nafiisah Chotun,et al. Successful Treatment of a South African Pediatric Case of Acute Liver Failure Caused by Perinatal Transmission of Hepatitis B , 2019, The Pediatric infectious disease journal.
[43] Ian Graber-Stiehl. The silent epidemic killing more people than HIV, malaria or TB , 2018, Nature.
[44] A. Hatzakis,et al. Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus , 2018, Front. Microbiol..
[45] J. Blackard,et al. In Silico Analysis of Hepatitis B Virus Occult Associated Mutations in Botswana Using a Novel Algorithm , 2018, Genes.
[46] A. Kramvis. Molecular characteristics and clinical relevance of African genotypes and subgenotypes of hepatitis B virus. , 2018, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[47] M. Sengayi,et al. Liver cancer mortality trends in South Africa: 1999–2015 , 2018, BMC Cancer.
[48] A. Hatzakis,et al. Unravelling the history of hepatitis B virus genotypes A and D infection using a full-genome phylogenetic and phylogeographic approach , 2018, eLife.
[49] A. Tita,et al. Elimination of Vertical Transmission of Hepatitis B in Africa: A Review of Available Tools and New Opportunities. , 2018, Clinical therapeutics.
[50] F. Fall,et al. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa , 2018, Expert review of gastroenterology & hepatology.
[51] W. Preiser,et al. HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa , 2018, BMC Infectious Diseases.
[52] J. Wylie,et al. Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities , 2018, Southern African journal of HIV medicine.
[53] A. Ely,et al. ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells , 2017, Scientific Reports.
[54] G. Theron,et al. Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience , 2017, PloS one.
[55] C. Marano,et al. The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience , 2017, Expert review of vaccines.
[56] A. Kramvis,et al. Expression of wild-type or G1862T mutant HBe antigen of subgenotype A1 of hepatitis B virus and the unfolded protein response in Huh7 cells. , 2017, The Journal of general virology.
[57] P. Kaleebu,et al. Hepatitis B serological markers and plasma DNA concentrations , 2017, AIDS.
[58] A. Ely,et al. Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs , 2017, Molecular therapy. Nucleic acids.
[59] Moganavelli Singh,et al. PEGylation potentiates hepatoma cell targeted liposome-mediated in vitro gene delivery via the asialoglycoprotein receptor , 2017, Zeitschrift fur Naturforschung. C, Journal of biosciences.
[60] Xiang He,et al. Higher prevalence of cancer related mutations 1762T/1764A and PreS deletions in hepatitis B virus (HBV) isolated from HBV/HIV co-infected compared to HBV-mono-infected Chinese adults. , 2017, Virus research.
[61] A. Ely,et al. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus. , 2016, Biochemical and biophysical research communications.
[62] J. Blackard,et al. Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[63] H. Hsu,et al. Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[64] A. Kramvis,et al. Hepatitis B e Antigen Expression by Hepatitis B Virus Subgenotype A1 Relative to Subgenotypes A2 and D3 in Cultured Hepatocellular Carcinoma (Huh7) Cells , 2016, Intervirology.
[65] R. Burnett,et al. High prevalence of active and occult hepatitis B virus infections in healthcare workers from two provinces of South Africa. , 2016, Vaccine.
[66] J. Blackard,et al. Functional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans. , 2016, The Journal of general virology.
[67] Zhichen Sun,et al. Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination , 2016, The Journal of Immunology.
[68] Moganavelli Singh,et al. Active targeting of asiaglycoprotein receptor using sterically stabilized lipoplexes , 2016 .
[69] Gérard Krause,et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.
[70] M. Cotton,et al. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. , 2015, Vaccine.
[71] D. Scherman,et al. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. , 2015, Journal of Controlled Release.
[72] S. Kulkarni,et al. Comparison of HBV-active HAART regimens in an HIV–HBV multinational cohort: outcomes through 144 weeks , 2015, AIDS.
[73] Michael S. Rentz,et al. Mutations associated with occult hepatitis B in HIV‐positive South Africans , 2015, Journal of medical virology.
[74] Moganavelli Singh,et al. Stealth lipoplex decorated with triazole-tethered galactosyl moieties: a strong hepatotropic gene vector , 2015, Biotechnology Letters.
[75] J. Blackard,et al. Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variants. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[76] A. Ely,et al. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses , 2014, Gene Therapy.
[77] A. Kramvis. Genotypes and Genetic Variability of Hepatitis B Virus , 2014, Intervirology.
[78] H. Will,et al. Construction of replication competent plasmids of hepatitis B virus subgenotypes A1, A2 and D3 with authentic endogenous promoters. , 2014, Journal of virological methods.
[79] A. Ely,et al. Inhibition of Hepatitis B Virus Replication by Helper Dependent Adenoviral Vectors Expressing Artificial Anti-HBV Pri-miRs from a Liver-Specific Promoter , 2014, BioMed research international.
[80] F. Carrilho,et al. High prevalence of hepatitis B virus subgenotypes A1 and D4 in Maranhão state, Northeast Brazil. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[81] R. Burnett,et al. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa , 2014, Journal of medical virology.
[82] A. Ely,et al. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes , 2014, Antiviral therapy.
[83] M. Fälth,et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. , 2014, Gastroenterology.
[84] A. Kramvis,et al. Hepatitis B virus subgenotype A1 predominates in liver disease patients from Kerala, India. , 2013, World journal of gastroenterology.
[85] R. Walensky,et al. The Survival Benefits of Antiretroviral Therapy in South Africa , 2013, The Journal of infectious diseases.
[86] R. Chauhan,et al. Genotyping and molecular characterization of hepatitis B virus in liver disease patients in Kenya. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[87] R. Tedder,et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa☆ , 2013, Vaccine.
[88] A. Ely,et al. Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs. , 2013, Bioorganic & medicinal chemistry.
[89] T. F. Rinke de Wit,et al. HIV–HBV Coinfection in Southern Africa and the Effect of Lamivudine- Versus Tenofovir-Containing cART on HBV Outcomes , 2013, Journal of acquired immune deficiency syndromes.
[90] T. Cathomen,et al. Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[91] S. Lewin,et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[92] D. Paraskevis,et al. Subgenotype A1 of HBV – Tracing Human Migrations in and Out of Africa , 2013, Antiviral therapy.
[93] K. Newton,et al. South African guideline for the management of chronic hepatitis B: 2013. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[94] Moganavelli Singh,et al. Novel Targeted Liposomes Deliver siRNA to Hepatocellular Carcinoma Cells in vitro , 2012, Chemical biology & drug design.
[95] A. Sasco,et al. The Spectrum of Cancers in West Africa: Associations with Human Immunodeficiency Virus , 2012, PloS one.
[96] S. Yeh,et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. , 2012, Journal of hepatology.
[97] N. Martinson,et al. Hepatitis B Virus Infection in Human Immunodeficiency Virus Infected Southern African Adults: Occult or Overt – That Is the Question , 2012, PloS one.
[98] A. Ely,et al. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. , 2012, MicroRNA.
[99] A. Kramvis,et al. Genotyping and Molecular Characterization of Hepatitis B Virus from Human Immunodeficiency Virus-Infected Individuals in Southern Africa , 2012, PloS one.
[100] R. Tedder,et al. High HBV viral loads in HIV-infected pregnant women at a tertiary hospital, South Africa. , 2012, Journal of acquired immune deficiency syndromes.
[101] G. Raimondo,et al. Occult HBV infection , 2012, Seminars in Immunopathology.
[102] C. M. Martin,et al. Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro , 2012, Journal of viral hepatitis.
[103] M. Vermeulen,et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual‐donation nucleic acid testing in South Africa: estimated and observed window period risk , 2012, Transfusion.
[104] M. Maskew,et al. Prevalence of hepatitis B virus (HBV) co-infection in HBV serologically-negative South African HIV patients and retrospective evaluation of the clinical course of mono- and co-infection. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[105] Yuhua Gong,et al. The Naturally Occurring YMDD Mutation among Patients Chronically Infected HBV and Untreated with Lamivudine: A Systematic Review and Meta-Analysis , 2012, PloS one.
[106] J. Samal,et al. Molecular Mechanisms Underlying Occult Hepatitis B Virus Infection , 2012, Clinical Microbiology Reviews.
[107] P. Sogni,et al. High levels of serum hepatitis B virus DNA in patients with ‘anti‐HBc alone’: role of HBsAg mutants , 2011, Journal of viral hepatitis.
[108] Chung-Chieh Yu,et al. Factors associated with in vitro interferon-gamma production in tuberculosis. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.
[109] Eric B. Roesch,et al. Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs , 2010, Artificial DNA, PNA & XNA.
[110] M. Kew. Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. , 2010, World journal of hepatology.
[111] G. Cao,et al. Associations Between Hepatitis B Virus Mutations and the Risk of Hepatocellular Carcinoma: A Meta-Analysis , 2009, Journal of the National Cancer Institute.
[112] S. Mano,et al. A Genetic Variant of Hepatitis B Virus Divergent from Known Human and Ape Genotypes Isolated from a Japanese Patient and Provisionally Assigned to New Genotype J , 2009, Journal of Virology.
[113] I. Sanne,et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[114] Ju Zhang,et al. Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication , 2009, Journal of medical virology.
[115] R. Burnett,et al. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes , 2009, Journal of medical virology.
[116] A. Ely,et al. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles , 2009, Nucleic acids research.
[117] R. Burnett,et al. Increased detection of HBV DNA in HBsAg‐positive and HBsAg‐negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital , 2009, Journal of medical virology.
[118] Yukikazu Natori,et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. , 2009, Molecular pharmaceutics.
[119] C. Sabin,et al. Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case–control study , 2008, The Journal of general virology.
[120] P. Marion,et al. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. , 2008 .
[121] A. Ely,et al. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[122] C. Crowther,et al. A valine to phenylalanine mutation in the precore region of hepatitis B virus causes intracellular retention and impaired secretion of HBe‐antigen , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.
[123] D. Stram,et al. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus , 2008, Journal of medical virology.
[124] R. Burnett,et al. Mutations associated with lamivudine‐resistance in therapy‐naïve hepatitis B virus (HBV) infected patients with and without HIV co‐infection: Implications for antiretroviral therapy in HBV and HIV co‐infected South African patients , 2007, Journal of medical virology.
[125] Sheng-Nan Lu,et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. , 2007, Gastroenterology.
[126] M. Torbenson,et al. Hepatitis B viral DNA is methylated in liver tissues , 2007, Journal of viral hepatitis.
[127] A. Kramvis,et al. Molecular characterization of subgenotype A1 (subgroup Aa) of hepatitis B virus , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[128] M. Kew,et al. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[129] Samantha Barichievy,et al. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[130] N. Izumi,et al. Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens , 2006, Hepatology.
[131] Ding‐Shinn Chen,et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. , 2006, The Journal of infectious diseases.
[132] Colin W Shepard,et al. Hepatitis B virus infection: epidemiology and vaccination. , 2006, Epidemiologic reviews.
[133] Theresa A. Storm,et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.
[134] P. Marion,et al. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[135] Keith Bowman,et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.
[136] B. Polisky,et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication , 2005, Hepatology.
[137] Mimi C. Yu,et al. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu‐speaking sub‐saharan Africans , 2005, Journal of medical virology.
[138] G. Leroux-Roels,et al. Hepatitis B virus and human immunodeficiency virus co‐infection in sub‐Saharan Africa: a call for further investigation , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[139] G. François,et al. Hepatitis B virus genotypes. , 2005, Vaccine.
[140] Weida Huang,et al. Cost-effective method of siRNA preparation and its application to inhibit hepatitis B virus replication in HepG2 cells. , 2005, World journal of gastroenterology.
[141] P. Coursaget,et al. Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes , 2004, Intervirology.
[142] R. Gish,et al. A case‐control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D , 2004, Hepatology.
[143] M. Kew,et al. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. , 2004, The Journal of general virology.
[144] J. Wands,et al. Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. , 2003, Gastroenterology.
[145] H. Giladi,et al. Small interfering RNA inhibits hepatitis B virus replication in mice. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[146] Catherine H. Wu,et al. Inhibition of HBV replication by siRNA in a stable HBV‐producing cell line , 2003, Hepatology.
[147] M. Manns,et al. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. , 2003, Gastroenterology.
[148] G. Schreiber,et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection , 2003, Transfusion.
[149] K. Eguchi,et al. Short interfering RNA‐directed inhibition of hepatitis B virus replication , 2003, FEBS letters.
[150] B. Tennant. Hepatitis B: The Hunt for a Killer Virus , 2003, Nature Medicine.
[151] Ding-Shinn Chen,et al. Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.
[152] W. Owiredu,et al. Analysis of the complete genome of subgroup A' hepatitis B virus isolates from South Africa. , 2002, The Journal of general virology.
[153] R. Bernards,et al. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.
[154] P. Venter,et al. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. , 2001, Vaccine.
[155] M. Baptista,et al. High prevalence of 1762T 1764A mutations in the basic core promoter of hepatitis B virus isolated from black africans with hepatocellular carcinoma compared with asymptomatic carriers , 1999, Hepatology.
[156] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[157] M. Kew,et al. A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa. , 1997, The Journal of general virology.
[158] M. Kew,et al. Nucleic acid sequence analysis of the precore region of hepatitis B virus from sera of southern African black adult carriers of the virus , 1997, Hepatology.
[159] J. Stéphenne. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. , 1990, Vaccine.
[160] E. Scolnick,et al. Production and immunological analysis of recombinant hepatitis B vaccine. , 1986, The Journal of infection.
[161] H. Alter,et al. Landmark article Feb 15, 1965: A "new" antigen in leukemia sera. By Baruch S. Blumberg, Harvey J. Alter, and Sam Visnich. , 1984, JAMA.
[162] M. Hilleman,et al. Purified and inactivated human hepatitis B vaccine: progress report. , 1975, The American journal of the medical sciences.
[163] R. Purcell,et al. Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. , 1975, The American journal of the medical sciences.
[164] H. Alter,et al. A "NEW" ANTIGEN IN LEUKEMIA SERA. , 1965, JAMA.
[165] M. B. Maepa,et al. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. , 2020, Methods in molecular biology.
[166] World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. , 2019, Vaccine.
[167] M. Kew,et al. The effect of the G1888A mutation of subgenotype A1 of hepatitis B virus on the translation of the core protein. , 2012, Virus research.
[168] G. Keating,et al. Recombinant Hepatitis B Vaccine (Engerix-B®) , 2012, Drugs.
[169] R. Burnett,et al. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[170] M. Opravil,et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[171] G. Keating,et al. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. , 2003, Drugs.
[172] M. Kew,et al. Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma. , 1998, Journal of hepatology.
[173] S. Brunak,et al. SHORT COMMUNICATION Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites , 1997 .
[174] J. Wands,et al. Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes. , 1994, Journal of hepatology.
[175] Hepatitis A vaccines WHO position paper , 2022 .